Physician profile

Addias C Mervin

Obstetrics & Gynecology · Bakersfield, CA

NPI 1316392756

$400.01

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$218.45

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $170.65 2021-2023
Pfizer INC. $51.04 2022-2024
Organon LLC $34.10 2022-2023 Nexplanon
Hologic Sales and Service, LLC $24.17 2024 Aptima
Bayer Healthcare Pharmaceuticals INC. $23.84 2023
Daiichi Sankyo INC. $22.48 2022
Shield Therapeutics INC $20.60 2024
Amgen INC. $19.05 2022
Urovant Sciences INC $17.34 2022
Kowa Pharmaceuticals America, INC. $16.74 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Addias C Mervin

$400.01

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/2783902/addias-c-mervin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.